Clinical trials: sponsored by Novartis Pharmaceuticals
Diffuse Large B-cell Lymphoma
Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL): Inpatient and Outpatient Settings
A retrospective, non-interventional cohort study was used to address the study objectives. This study aimed to provide a better understanding of real-world healthcare resource utilization (HRU) and healthcare reimbursement costs…
- Trial name
- NCT05918809
- Where
- United States
- Volunteers
- 1,031 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myocardial Infarction
Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily.
- Trial name
- PARADISE-MI (NCT02924727)
- Testing
- LCZ696 (sacubitril/valsartan), Ramipril, Valsartan
- Where
- 486 sites in United States, Argentina and 39 more
- Volunteers
- 5,669 people
- Sponsor
- Novartis Pharmaceuticals
Non Small Cell Lung Cancer
Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.
The purpose of this study was to determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of nazartinib (EGF816) in combination with capmatinib (INC280) and to estimate the preliminary anti-tumor activity of…
- Trial name
- NCT02335944
- Testing
- Capmatinib, Nazartinib
- Where
- 19 sites in United States, Australia and 9 more
- Volunteers
- 177 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloid Leukaemia
Real-World Disease Management and Outcomes in Chronic Myeloid Leukaemia
Chronic myeloid leukaemia (CML) diagnosis is based on the demonstration of a BCR-ABL fusion transcript expressed by the Philadelphia (Ph) chromosome by RQ-PCR and/or the demonstration of t(9;22)(q34;q11) by conventional…
- Trial name
- NCT05893836
- Where
- United Kingdom
- Volunteers
- 555 people
- Sponsor
- Novartis Pharmaceuticals
Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
The purpose of the Phase Ib is to: 1. determine the recommended dose of LEE011 in combination with a standard dose of letrozole as well as to provide additional safety and anti-tumor activity data in Asian non-Japanese patients…
- Trial name
- NCT02333370
- Testing
- LEE011, Letrozole, Tamoxifen
- Where
- 15 sites in Hong Kong, Japan and 1 more
- Volunteers
- 88 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
The 'Wearing Off' Effect of DMT
This is a non-interventional, cross-sectional, qualitative study in which patients diagnosed with MS and clinicians with experience treating MS will be interviewed regarding patient experiences with the wearing off effect from…
- Trial name
- NCT05627271
- Testing
- ocrelizumab, natalizumab, ofatumumab
- Where
- Switzerland
- Volunteers
- 39 people
- Sponsor
- Novartis Pharmaceuticals
Malignant Melanoma
Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)
The primary objective for this non-interventional study was to assess the quality of life of melanoma patients under adjuvant treatment with dabrafenib and trametinib in real world setting in Portugal through disease specific…
- Trial name
- NCT04547946
- Testing
- dabrafenib + trametinib
- Where
- 2 sites in Portugal
- Volunteers
- 3 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma
Retrospective Assessment of AE-Related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma
This was a retrospective cohort study using Truven Health Analytics' MarketScan Commercial Claims and Encounters and Medicare Supplement and Coordination of Benefit administrative claims databases.
- Trial name
- NCT05874817
- Where
- United States
- Volunteers
- 17,517 people
- Sponsor
- Novartis Pharmaceuticals
High Levels of Low-density Lipoprotein Cholesterol
Adherence and Persistence to Inclisiran Among Early Users in Germany
The present study was a descriptive, non-interventional, retrospective cohort study aimed at evaluating early data on adherence, persistence, and treatment patterns among patients receiving inclisiran and other lipid-lowering…
- Trial name
- NCT05870657
- Where
- Switzerland
- Volunteers
- 1,109 people
- Sponsor
- Novartis Pharmaceuticals
Amblyopia
Proof of Concept Study of Binocular Videogames Versus Patching for Amblyopia
The purpose of this PoC study was to evaluate the potential therapeutic efficacy of binocular video games played on a tablet and to compare the efficacy of binocular video games versus patching in amblyopic patients 4 to 7 years…
- Trial name
- NCT04784390
- Testing
- Binocular video games, Patching of the sound eye
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction Patients: a Real World Study in India
This was a non-interventional, retrospective EMR analysis of longitudinal prescriptions in India for a period of 1.5 years. Demographic profile of patients with heart failure with reduced ejection fraction on sacubitril/valsartan…
- Trial name
- NCT04735354
- Testing
- sacubitril/valsartan
- Where
- India
- Volunteers
- 268 people
- Sponsor
- Novartis Pharmaceuticals
HR+/HER2- Advanced or Metastatic Breast Cancer
A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of Therapy
This was a non-interventional, retrospective cohort study of patients with HR+/HER2- aBC treated with alpelisib (ALP) plus fulvestrant (FUL) who have received fulvestrant in any prior line of therapy (LoT).
- Trial name
- NCT05853432
- Where
- Ireland
- Volunteers
- 157 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Heart Failure
Impact of Formulary Coverage of Entresto (Sacubitril/Valsartan) on Prescription Abandonment/Rejection and Subsequent Treatment and Economic Outcomes in Chronic Heart Failure Patients in the U.S.
This was a retrospective cohort study utilizing IQVIA open-source pharmacy and medical claims data among patients with a sacubitril/valsartan (SAC/VAL) prescription transaction.
- Trial name
- NCT05848206
- Where
- United States
- Volunteers
- 251,831 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Melanoma
Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib
This was a retrospective cohort study using the MarketScan health care administrative claim databases: Truven Health Analytics' MarketScan Commercial Claims and Encounters; MarketScan Medicare Supplement and Coordination of…
- Trial name
- NCT05848219
- Where
- United States
- Volunteers
- 543 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Heart Failure
Special Drug Use Surveillance for Entresto Tablets
This is a single arm, multicenter, observational study in Japanese chronic heart failure patients.
- Trial name
- NCT04781881
- Testing
- Entresto
- Where
- 121 sites in Japan
- Volunteers
- 688 people
- Sponsor
- Novartis Pharmaceuticals
Hormone Receptor Positive Breast Cancer
Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer
The purpose of this study was to assess the efficacy and safety of first-line treatment with everolimus plus letrozole in postmenopausal women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2…
- Trial name
- BOLERO-4 (NCT01698918)
- Testing
- Everolimus, Letrozole, Exemestane
- Where
- 52 sites in United States, Argentina and 11 more
- Volunteers
- 202 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients
This clinical study was designed to support the dose selection for future studies by evaluating efficacy and safety of different QBW251 doses in Chronic obstructive pulmonary disease (COPD) patients with chronic bronchitis and a…
- Trial name
- NCT04072887
- Testing
- QBW251, COPD maintenance background therapy
- Where
- 148 sites in United States, Argentina and 24 more
- Volunteers
- 974 people
- Sponsor
- Novartis Pharmaceuticals
Neurovascular Age-related Macular Degeneration
A Retrospective Study to Evaluate the Early Real-world Evidence of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD) in India
This non-interventional, retrospective, observational, noncomparative, non-randomized, single-arm, multi-centre study included patients (≥50 years) diagnosed with neovascular age-related macular degeneration (nAMD) in at least 1…
- Trial name
- NCT05834075
- Where
- 4 sites in India
- Volunteers
- 63 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myelogenous Leukemia (CML)
Nilotinib, for Patients With CML-CP or CML-AP
The purpose of this Cohort Treatment Plan is to allow access to Nilotinib for eligible patients diagnosed with imatinib-intolerant and/or resistant Philadelphia Chromosome positive (Ph+) Chronic Myelogenous Leukemia in Chronic…
- Trial name
- NCT04518644
- Testing
- Nilotinib
- Sponsor
- Novartis Pharmaceuticals
Neoplasms, Breast
ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib
This study was originally designed as a Phase III randomized, double blind, placebo controlled study to assess the safety and tolerability, and efficacy of paclitaxel plus trastuzumab plus lapatinib compared with paclitaxel plus…
- Trial name
- NCT00272987
- Testing
- lapatinib, paclitaxel, trastuzumab
- Where
- 16 sites in United States, Belgium
- Volunteers
- 63 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.